Cancer Therapies

IL-2 Cancer Gene Medicine Phase I Clinical Trial Commences

Published in Gene Therapy Weekly, September 8th, 1997

Genemedicine, Inc., The Woodlands, Texas, announced that it has commenced the first Phase I human clinical trial for its Interleukin-2 (IL-2) Cancer Gene Medicine that is being developed for the treatment of head and neck cancer.

The clinical trial is being conducted at Johns Hopkins medical institutions, Baltimore, Maryland. The IL-2 Cancer Gene Medicine is the first product to result from the corporate alliance Genemedicine formed with Boehringer Mannheim in July 1995. An additional Phase I human clinical trial to be conducted in Germany in collaboration with Boehringer Mannheim is expected to begin in the next few weeks.

"This marks the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-09-08)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry